BioCentury
ARTICLE | Company News

Valneva, InFlectis deal

March 16, 2015 7:00 AM UTC

Valneva granted InFlectis exclusive, worldwide rights to the protein-protein interaction drug discovery platform 3D-Screen for all indications except HCV infection. InFlectis may use the technology to...